Mycosis fungoides primary prevention: Difference between revisions
Jump to navigation
Jump to search
(4 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Mycosis fungoides}} | ||
{{CMG}}; {{AE}} {{S.G.}} | {{CMG}}; {{AE}} {{S.G.}} | ||
Line 6: | Line 6: | ||
* There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the [[secondary]] [[Prevention (medical)|prevention]] of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks. | * There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the [[secondary]] [[Prevention (medical)|prevention]] of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks. | ||
== | ==Primary Prevention== | ||
* | *There are no established [[Risk factor|risk factors]] for mycosis fungoides. | ||
* The [[Risk factor|risk factors]] in the development of mycosis fungoides is environmental and occupational exposure include <ref>{{Cite journal | |||
| author = [[A. S. Whittemore]], [[E. A. Holly]], [[I. M. Lee]], [[E. A. Abel]], [[R. M. Adams]], [[B. J. Nickoloff]], [[L. Bley]], [[J. M. Peters]] & [[C. Gibney]] | |||
| title = Mycosis fungoides in relation to environmental exposures and immune response: a case-control study | |||
| journal = [[Journal of the National Cancer Institute]] | |||
| volume = 81 | |||
| issue = 20 | |||
| pages = 1560–1567 | |||
| year = 1989 | |||
| month = October | |||
| pmid = 2795681 | |||
}}</ref><ref name="pmid1857968">{{cite journal |vauthors=Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A |title=Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides |journal=Science |volume=253 |issue=5017 |pages=317–20 |date=July 1991 |pmid=1857968 |doi= |url=}}</ref><ref>{{Cite journal | |||
| author = [[S. K. Ghosh]], [[J. T. Abrams]], [[H. Terunuma]], [[E. C. Vonderheid]] & [[E. DeFreitas]] | |||
| title = Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma | |||
| journal = [[Blood]] | |||
| volume = 84 | |||
| issue = 8 | |||
| pages = 2663–2671 | |||
| year = 1994 | |||
| month = October | |||
| pmid = 7522638 | |||
}}</ref> | |||
**[[Bacterial infection]] of the [[skin]] | |||
**Long term exposure to [[chemicals]] | |||
**[[Smoking]] | |||
**[[Medication|Medications]] | |||
**Long term [[sun exposure]] | |||
**[[Viral infections]] (Human T lymphotropic virus type I) | |||
==References== | ==References== |
Latest revision as of 04:05, 11 February 2019
Mycosis fungoides Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Mycosis fungoides primary prevention On the Web |
American Roentgen Ray Society Images of Mycosis fungoides primary prevention |
Risk calculators and risk factors for Mycosis fungoides primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
- There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
Primary Prevention
- There are no established risk factors for mycosis fungoides.
- The risk factors in the development of mycosis fungoides is environmental and occupational exposure include [1][2][3]
- Bacterial infection of the skin
- Long term exposure to chemicals
- Smoking
- Medications
- Long term sun exposure
- Viral infections (Human T lymphotropic virus type I)
References
- ↑ A. S. Whittemore, E. A. Holly, I. M. Lee, E. A. Abel, R. M. Adams, B. J. Nickoloff, L. Bley, J. M. Peters & C. Gibney (1989). "Mycosis fungoides in relation to environmental exposures and immune response: a case-control study". Journal of the National Cancer Institute. 81 (20): 1560–1567. PMID 2795681. Unknown parameter
|month=
ignored (help) - ↑ Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A (July 1991). "Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides". Science. 253 (5017): 317–20. PMID 1857968.
- ↑ S. K. Ghosh, J. T. Abrams, H. Terunuma, E. C. Vonderheid & E. DeFreitas (1994). "Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma". Blood. 84 (8): 2663–2671. PMID 7522638. Unknown parameter
|month=
ignored (help)